- Home
- AB vs KNSA Comparison
AB vs KNSA Comparison
Compare AB & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AB | KNSA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AB | KNSA |
|---|---|---|
| Price | $37.20 | $46.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $42.00 | ★ $55.29 |
| AVG Volume (30 Days) | 325.6K | ★ 623.2K |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 9.21% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $38.01 |
| Revenue Next Year | $7.40 | $17.42 |
| P/E Ratio | ★ $13.85 | $61.12 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $32.28 | $18.26 |
| 52 Week High | $44.11 | $49.12 |
Technical Indicators
Market Signals| Indicator | AB | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 55.81 |
| Support Level | N/A | $44.36 |
| Resistance Level | $39.97 | $48.14 |
| Average True Range (ATR) | 1.01 | 1.53 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 23.28 | 72.33 |
Price Performance
Historical ComparisonAbout AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (41%), and private (18%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of January 2026, the company had $875.0 billion in managed assets, composed primarily of fixed-income (36% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.